Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7


Identification of potential therapeutic targets in prostate cancer through a cross-species approach.

Jurmeister S, Ramos-Montoya A, Sandi C, Pértega-Gomes N, Wadhwa K, Lamb AD, Dunning MJ, Attig J, Carroll JS, Fryer LG, Felisbino SL, Neal DE.

EMBO Mol Med. 2018 Mar;10(3). pii: e8274. doi: 10.15252/emmm.201708274.


A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy.

Pertega-Gomes N, Felisbino S, Massie CE, Vizcaino JR, Coelho R, Sandi C, Simoes-Sousa S, Jurmeister S, Ramos-Montoya A, Asim M, Tran M, Oliveira E, Lobo da Cunha A, Maximo V, Baltazar F, Neal DE, Fryer LG.

J Pathol. 2015 Aug;236(4):517-30. doi: 10.1002/path.4547.


Transcriptomic analysis reveals inhibition of androgen receptor activity by AMPK in prostate cancer cells.

Jurmeister S, Ramos-Montoya A, Neal DE, Fryer LG.

Oncotarget. 2014 Jun 15;5(11):3785-99.


A lactate shuttle system between tumour and stromal cells is associated with poor prognosis in prostate cancer.

Pértega-Gomes N, Vizcaíno JR, Attig J, Jurmeister S, Lopes C, Baltazar F.

BMC Cancer. 2014 May 21;14:352. doi: 10.1186/1471-2407-14-352.


HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network.

Ramos-Montoya A, Lamb AD, Russell R, Carroll T, Jurmeister S, Galeano-Dalmau N, Massie CE, Boren J, Bon H, Theodorou V, Vias M, Shaw GL, Sharma NL, Ross-Adams H, Scott HE, Vowler SL, Howat WJ, Warren AY, Wooster RF, Mills IG, Neal DE.

EMBO Mol Med. 2014 May;6(5):651-61. doi: 10.1002/emmm.201303581.


Downregulation of androgen receptor transcription by promoter g-quadruplex stabilization as a potential alternative treatment for castrate-resistant prostate cancer.

Mitchell T, Ramos-Montoya A, Di Antonio M, Murat P, Ohnmacht S, Micco M, Jurmeister S, Fryer L, Balasubramanian S, Neidle S, Neal DE.

Biochemistry. 2013 Feb 26;52(8):1429-36. doi: 10.1021/bi301349c. Epub 2013 Feb 11.


MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F.

Jurmeister S, Baumann M, Balwierz A, Keklikoglou I, Ward A, Uhlmann S, Zhang JD, Wiemann S, Sahin Ö.

Mol Cell Biol. 2012 Feb;32(3):633-51. doi: 10.1128/MCB.06212-11. Epub 2011 Dec 5.

Supplemental Content

Loading ...
Support Center